An Australian pharmaceutical firm that is developing the first virus-killing nasal spray for colds is set to be listed on the ASX on Jan. 28. Firebrick Pharma co-founder Peter Molloy said he’s been working on the spray, Nasodine, for almost ten years as a treatment for the common cold. “It appeared to me that if you could kill the viruses that are present in the nose, you could intervene in the course of the common cold and stop it spreading in the body and to other people,” he said. Common colds can be caused by about 200 viruses, therefore a nasal spray that targets all causes of common colds require a broad-spectrum treatment, Molloy said in a video. The spray is based on povidone-iodine, the same active ingredient found in Betadine throat gargle, which Molloy developed earlier in his career. A usual concern for broad-spectrum treatment is that it can cause …